| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Department of Nephrology and Hypertension (H.P.H.N., B.U.B.), Department of Gastroenterology and Endocrinology (M.R.), Albert-Ludwigs-University, D-79106 Freiburg, Germany; Department of Pediatrics (R.E.), Maximilian-University, D-80337 Munich, Germany; Department of Urology (G.J.) Leopold-Franzens-University, A-6020 Innsbruck, Austria
Address correspondence and requests for reprints to: Professor Dr. H. P. H. Neumann, Medizinische Universitätsklinik, Hugstetter Straße 55, D-79106 Freiburg, Germany. E-mail:
Background: Familial pheochromocytoma, increasingly diagnosed in asymptomatic subjects with inherited syndromes such as multiple endocrine neoplasia type 2 and Von Hippel-Lindau disease, is frequently bilateral and multifocal, but very rarely malignant. Therefore, bilateral adrenalectomy and subsequent lifelong steroid replacement, with its attendent side effects, is not desirable. Minimally invasive adrenal sparing surgery by means of laparoscopy was explored for the treatment of bilateral pheochromocytoma. We report on the cure rate and adrenocortical function in a series of patients treated accordingly.
Patients and methods: Four patients (three male, one female, ages 960 yr) with hereditary bilateral adrenal pheochromocytoma were treated by laparoscopic surgery in an organ sparing fashion. Postoperatively, all patients were reevaluated for complete tumor removal and for adrenocortical function.
Results: Two to 24 months after surgery, all patients were normotensive, had normal sodium potassium, glucose, aldosterone, renin, and cortisol serum concentrations, 24-h excretion of norepinephrine, epinephrine, and vanillylmandelic acid. Abdominal magnetic resonance imaging (n = 3) and computed tomographic scan (n = 1) disclosed no remnant or relapsing tumor tissue. ACTH stimulation testing resulted in normal cortisol responses.
Conclusion: By adrenal sparing laparoscopic surgery not only bilateral pheochromocytoma can be successfully removed, but also adrenocortical function preserved. This may become the treatment of choice for familial pheochromocytoma.
This article has been cited by other articles:
![]() |
R. Asari, C. Scheuba, K. Kaczirek, and B. Niederle Estimated Risk of Pheochromocytoma Recurrence After Adrenal-Sparing Surgery in Patients With Multiple Endocrine Neoplasia Type 2A Arch Surg, December 1, 2006; 141(12): 1199 - 1205. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. P. H. Neumann, C. Pawlu, M. Peczkowska, B. Bausch, S. R. McWhinney, M. Muresan, M. Buchta, G. Franke, J. Klisch, T. A. Bley, et al. Distinct Clinical Features of Paraganglioma Syndromes Associated With SDHB and SDHD Gene Mutations JAMA, August 25, 2004; 292(8): 943 - 951. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Baghai, G. B. Thompson, W. F. Young Jr, C. S. Grant, V. V. Michels, and J. A. van Heerden Pheochromocytomas and Paragangliomas in von Hippel-Lindau Disease: A Role for Laparoscopic and Cortical-Sparing Surgery Arch Surg, June 1, 2002; 137(6): 682 - 689. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |